234 related articles for article (PubMed ID: 27241239)
1. Intravenous immunoglobulin treatment in chronic inflammatory demyelinating polyradiculoneuropathy, a time to start and a time to stop.
Adrichem ME; Eftimov F; van Schaik IN
J Peripher Nerv Syst; 2016 Sep; 21(3):121-7. PubMed ID: 27241239
[TBL] [Abstract][Full Text] [Related]
2. Long-term effects of intravenous immunoglobulin in CIDP.
Vucic S; Black K; Baldassari LE; Tick Chong PS; Dawson KT; Cros D
Clin Neurophysiol; 2007 Sep; 118(9):1980-4. PubMed ID: 17604689
[TBL] [Abstract][Full Text] [Related]
3. Serum IgG levels as biomarkers for optimizing IVIg therapy in CIDP.
van Doorn PA; Kuitwaard K; Jacobs BC
J Peripher Nerv Syst; 2011 Jun; 16 Suppl 1():38-40. PubMed ID: 21696496
[TBL] [Abstract][Full Text] [Related]
4. Intravenous immunoglobulin for chronic inflammatory demyelinating polyradiculoneuropathy: the ICE trial.
Hughes RA
Expert Rev Neurother; 2009 Jun; 9(6):789-95. PubMed ID: 19496683
[TBL] [Abstract][Full Text] [Related]
5. Intravenous immunoglobulin versus intravenous methylprednisolone for chronic inflammatory demyelinating polyradiculoneuropathy: a randomised controlled trial.
Nobile-Orazio E; Cocito D; Jann S; Uncini A; Beghi E; Messina P; Antonini G; Fazio R; Gallia F; Schenone A; Francia A; Pareyson D; Santoro L; Tamburin S; Macchia R; Cavaletti G; Giannini F; Sabatelli M;
Lancet Neurol; 2012 Jun; 11(6):493-502. PubMed ID: 22578914
[TBL] [Abstract][Full Text] [Related]
6. Subcutaneous immunoglobulin infusion: a new therapeutic option in chronic inflammatory demyelinating polyneuropathy.
Lee DH; Linker RA; Paulus W; Schneider-Gold C; Chan A; Gold R
Muscle Nerve; 2008 Mar; 37(3):406-9. PubMed ID: 17918749
[TBL] [Abstract][Full Text] [Related]
7. Systematic reviews of treatment for chronic inflammatory demyelinating neuropathy.
Hughes RA
Rev Neurol (Paris); 2002 Dec; 158(12 Pt 2):S32-6. PubMed ID: 12690659
[TBL] [Abstract][Full Text] [Related]
8. Randomised controlled trial comparing two different intravenous immunoglobulins in chronic inflammatory demyelinating polyradiculoneuropathy.
Kuitwaard K; van den Berg LH; Vermeulen M; Brusse E; Cats EA; van der Kooi AJ; Notermans NC; van der Pol WL; van Schaik IN; van Nes SI; Hop WC; van Doorn PA
J Neurol Neurosurg Psychiatry; 2010 Dec; 81(12):1374-9. PubMed ID: 20587484
[TBL] [Abstract][Full Text] [Related]
9. Treatment of chronic inflammatory demyelinating polyneuropathy with high-dose intermittent intravenous methylprednisolone.
Lopate G; Pestronk A; Al-Lozi M
Arch Neurol; 2005 Feb; 62(2):249-54. PubMed ID: 15710853
[TBL] [Abstract][Full Text] [Related]
10. [Treatment options for chronic inflammatory demyelinating polyradiculoneuropathy (CIDP)].
Kuntzer T
Rev Neurol (Paris); 2006 Apr; 162(4):539-43. PubMed ID: 16585918
[TBL] [Abstract][Full Text] [Related]
11. Investigations and treatment of chronic inflammatory demyelinating polyradiculoneuropathy and other inflammatory demyelinating polyneuropathies.
Tracy JA; Dyck PJ
Curr Opin Neurol; 2010 Jun; 23(3):242-8. PubMed ID: 20389243
[TBL] [Abstract][Full Text] [Related]
12. [Efficacy and availability of intravenous immunoglobulin in chronic inflammatory demyelinating polyneuropathy].
Iijima M; Koike H; Sobue G
Nihon Rinsho; 2012 Apr; 70(4):715-21. PubMed ID: 22568158
[TBL] [Abstract][Full Text] [Related]
13. Potential biomarkers for monitoring therapeutic response in patients with CIDP.
Dalakas MC
J Peripher Nerv Syst; 2011 Jun; 16 Suppl 1():63-7. PubMed ID: 21696503
[TBL] [Abstract][Full Text] [Related]
14. Chronic inflammatory demyelinating polyradiculoneuropathy in solid organ transplant recipients: a prospective study.
Echaniz-Laguna A; de Séze J; Chanson JB
J Neurol Neurosurg Psychiatry; 2012 Jul; 83(7):699-705. PubMed ID: 22577230
[TBL] [Abstract][Full Text] [Related]
15. Immunomodulatory effects of intravenous and subcutaneous immunoglobulin in chronic inflammatory demyelinating polyneuropathy: An observational study.
Svačina MKR; Meißner A; Schweitzer F; Ladwig A; Pitarokoili K; Kofler DM; Sprenger-Svačina A; Schneider C; Kohle F; Klein I; Wüstenberg H; Lehmann HC
Eur J Neurol; 2024 Jan; 31(1):e16079. PubMed ID: 37789648
[TBL] [Abstract][Full Text] [Related]
16. Randomized controlled trial of IVIg in untreated chronic inflammatory demyelinating polyradiculoneuropathy.
Mendell JR; Barohn RJ; Freimer ML; Kissel JT; King W; Nagaraja HN; Rice R; Campbell WW; Donofrio PD; Jackson CE; Lewis RA; Shy M; Simpson DM; Parry GJ; Rivner MH; Thornton CA; Bromberg MB; Tandan R; Harati Y; Giuliani MJ;
Neurology; 2001 Feb; 56(4):445-9. PubMed ID: 11222785
[TBL] [Abstract][Full Text] [Related]
17. The role of IVIg in autoimmune neuropathies: the latest evidence.
Hughes R
J Neurol; 2008 Jul; 255 Suppl 3():7-11. PubMed ID: 18685920
[TBL] [Abstract][Full Text] [Related]
18. Subcutaneous immunoglobulin in responders to intravenous therapy with chronic inflammatory demyelinating polyradiculoneuropathy.
Markvardsen LH; Debost JC; Harbo T; Sindrup SH; Andersen H; Christiansen I; Otto M; Olsen NK; Lassen LL; Jakobsen J;
Eur J Neurol; 2013 May; 20(5):836-42. PubMed ID: 23294032
[TBL] [Abstract][Full Text] [Related]
19. Intravenous immunoglobulin for chronic inflammatory demyelinating polyradiculoneuropathy: a systematic review.
van Schaik IN; Winer JB; de Haan R; Vermeulen M
Lancet Neurol; 2002 Dec; 1(8):491-8. PubMed ID: 12849334
[TBL] [Abstract][Full Text] [Related]
20. The effect of IgG levels on the number of natural killer cells and their Fc receptors in chronic inflammatory demyelinating polyradiculoneuropathy.
Bohn AB; Nederby L; Harbo T; Skovbo A; Vorup-Jensen T; Krog J; Jakobsen J; Hokland ME
Eur J Neurol; 2011 Jun; 18(6):919-24. PubMed ID: 21219545
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
